Clinical significance of frusemide stress test in predicting the severity of acute kidney injury

Detalhes bibliográficos
Autor(a) principal: Pon,Arun Gokul
Data de Publicação: 2021
Outros Autores: Vairakkani,Raveendran, Mervin,Edwin Fernando, Srinivasaprasad,Nagalakshmi Dhanapal, Kaliaperumal,Thirumalvalavan
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Jornal Brasileiro de Nefrologia
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002021000400470
Resumo: Abstract Introduction: The outcomes of Acute Kidney Injury (AKI) remain dismal even today, owing in part due to the lack of an ideal biomarker for detecting renal damage early enough. We conducted this pilot study to determine the clinical significance of Frusemide Stress Test (FST) to predict the severity of AKI. Methods: A total of 80 patients with AKI-KDIGO (Kidney Disease: Improving Global Outcomes) stage 1 or stage 2 underwent FST by administering a bolus dose of frusemide (1mg/kg for frusemide naïve and 1.5mg/kg for prior frusemide exposure in the past week), and urine output was then measured for the next two hours with volume replacement as desirable. The progression to AKI-KDIGO stage 3 within 14 days of FST was studied as the primary outcome. The composite end point of achieving AKI-KDIGO stage 3 or death within 14 days of FST was studied as the secondary outcome. Results: Out of 80 patients, 28(35%) patients met the primary outcome, and 34(42.5%) patients met the secondary composite outcome. Except for baseline Chronic Kidney Disease (CKD) status (p=0.018), other demographic characteristics were comparable between progressors and non-progressors group. Using receiver operating characteristics (ROC) curve analysis, a cumulative 2-hour post-FST urine output of ≤300 mL predicted progression to stage 3 AKI with 82.14% sensitivity, 82.69% specificity, and AUC of 0.89±0.03 (p<0.0001). Conclusion: The FST showed promising results as a novel tubular biomarker to identify progression to severe AKI with good predictive ability.
id SBN-1_f3db7fcb96b16dbf8450af7f6c3021dd
oai_identifier_str oai:scielo:S0101-28002021000400470
network_acronym_str SBN-1
network_name_str Jornal Brasileiro de Nefrologia
repository_id_str
spelling Clinical significance of frusemide stress test in predicting the severity of acute kidney injuryAcute Kidney InjuryFurosemideExercise TestAbstract Introduction: The outcomes of Acute Kidney Injury (AKI) remain dismal even today, owing in part due to the lack of an ideal biomarker for detecting renal damage early enough. We conducted this pilot study to determine the clinical significance of Frusemide Stress Test (FST) to predict the severity of AKI. Methods: A total of 80 patients with AKI-KDIGO (Kidney Disease: Improving Global Outcomes) stage 1 or stage 2 underwent FST by administering a bolus dose of frusemide (1mg/kg for frusemide naïve and 1.5mg/kg for prior frusemide exposure in the past week), and urine output was then measured for the next two hours with volume replacement as desirable. The progression to AKI-KDIGO stage 3 within 14 days of FST was studied as the primary outcome. The composite end point of achieving AKI-KDIGO stage 3 or death within 14 days of FST was studied as the secondary outcome. Results: Out of 80 patients, 28(35%) patients met the primary outcome, and 34(42.5%) patients met the secondary composite outcome. Except for baseline Chronic Kidney Disease (CKD) status (p=0.018), other demographic characteristics were comparable between progressors and non-progressors group. Using receiver operating characteristics (ROC) curve analysis, a cumulative 2-hour post-FST urine output of ≤300 mL predicted progression to stage 3 AKI with 82.14% sensitivity, 82.69% specificity, and AUC of 0.89±0.03 (p<0.0001). Conclusion: The FST showed promising results as a novel tubular biomarker to identify progression to severe AKI with good predictive ability.Sociedade Brasileira de Nefrologia2021-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002021000400470Brazilian Journal of Nephrology v.43 n.4 2021reponame:Jornal Brasileiro de Nefrologiainstname:Sociedade Brasileira de Nefrologia (SBN)instacron:SBN10.1590/2175-8239-jbn-2021-0003info:eu-repo/semantics/openAccessPon,Arun GokulVairakkani,RaveendranMervin,Edwin FernandoSrinivasaprasad,Nagalakshmi DhanapalKaliaperumal,Thirumalvalavaneng2021-12-06T00:00:00Zoai:scielo:S0101-28002021000400470Revistahttp://www.bjn.org.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||jbn@sbn.org.br2175-82390101-2800opendoar:2021-12-06T00:00Jornal Brasileiro de Nefrologia - Sociedade Brasileira de Nefrologia (SBN)false
dc.title.none.fl_str_mv Clinical significance of frusemide stress test in predicting the severity of acute kidney injury
title Clinical significance of frusemide stress test in predicting the severity of acute kidney injury
spellingShingle Clinical significance of frusemide stress test in predicting the severity of acute kidney injury
Pon,Arun Gokul
Acute Kidney Injury
Furosemide
Exercise Test
title_short Clinical significance of frusemide stress test in predicting the severity of acute kidney injury
title_full Clinical significance of frusemide stress test in predicting the severity of acute kidney injury
title_fullStr Clinical significance of frusemide stress test in predicting the severity of acute kidney injury
title_full_unstemmed Clinical significance of frusemide stress test in predicting the severity of acute kidney injury
title_sort Clinical significance of frusemide stress test in predicting the severity of acute kidney injury
author Pon,Arun Gokul
author_facet Pon,Arun Gokul
Vairakkani,Raveendran
Mervin,Edwin Fernando
Srinivasaprasad,Nagalakshmi Dhanapal
Kaliaperumal,Thirumalvalavan
author_role author
author2 Vairakkani,Raveendran
Mervin,Edwin Fernando
Srinivasaprasad,Nagalakshmi Dhanapal
Kaliaperumal,Thirumalvalavan
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Pon,Arun Gokul
Vairakkani,Raveendran
Mervin,Edwin Fernando
Srinivasaprasad,Nagalakshmi Dhanapal
Kaliaperumal,Thirumalvalavan
dc.subject.por.fl_str_mv Acute Kidney Injury
Furosemide
Exercise Test
topic Acute Kidney Injury
Furosemide
Exercise Test
description Abstract Introduction: The outcomes of Acute Kidney Injury (AKI) remain dismal even today, owing in part due to the lack of an ideal biomarker for detecting renal damage early enough. We conducted this pilot study to determine the clinical significance of Frusemide Stress Test (FST) to predict the severity of AKI. Methods: A total of 80 patients with AKI-KDIGO (Kidney Disease: Improving Global Outcomes) stage 1 or stage 2 underwent FST by administering a bolus dose of frusemide (1mg/kg for frusemide naïve and 1.5mg/kg for prior frusemide exposure in the past week), and urine output was then measured for the next two hours with volume replacement as desirable. The progression to AKI-KDIGO stage 3 within 14 days of FST was studied as the primary outcome. The composite end point of achieving AKI-KDIGO stage 3 or death within 14 days of FST was studied as the secondary outcome. Results: Out of 80 patients, 28(35%) patients met the primary outcome, and 34(42.5%) patients met the secondary composite outcome. Except for baseline Chronic Kidney Disease (CKD) status (p=0.018), other demographic characteristics were comparable between progressors and non-progressors group. Using receiver operating characteristics (ROC) curve analysis, a cumulative 2-hour post-FST urine output of ≤300 mL predicted progression to stage 3 AKI with 82.14% sensitivity, 82.69% specificity, and AUC of 0.89±0.03 (p<0.0001). Conclusion: The FST showed promising results as a novel tubular biomarker to identify progression to severe AKI with good predictive ability.
publishDate 2021
dc.date.none.fl_str_mv 2021-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002021000400470
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002021000400470
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/2175-8239-jbn-2021-0003
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Nefrologia
publisher.none.fl_str_mv Sociedade Brasileira de Nefrologia
dc.source.none.fl_str_mv Brazilian Journal of Nephrology v.43 n.4 2021
reponame:Jornal Brasileiro de Nefrologia
instname:Sociedade Brasileira de Nefrologia (SBN)
instacron:SBN
instname_str Sociedade Brasileira de Nefrologia (SBN)
instacron_str SBN
institution SBN
reponame_str Jornal Brasileiro de Nefrologia
collection Jornal Brasileiro de Nefrologia
repository.name.fl_str_mv Jornal Brasileiro de Nefrologia - Sociedade Brasileira de Nefrologia (SBN)
repository.mail.fl_str_mv ||jbn@sbn.org.br
_version_ 1752122066967986176